Biotech giant Bristol-Myers Squibb Company BMY is scheduled to report first-quarter 2025 results on April 24, before market ...

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders ...

Bristol Myers Squibb BMY suffered a setback in the late-stage ODYSSEY-HCM study evaluating cardiovascular drug Camzyos ...

The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in ...

Oppenheimer lifted its rating on Roblox Corp (NYSE:RBLX) shares to Outperform with a price target (PT) of $70. The upgrade comes in the wake of a recent decline in the stock, which has plummeted 24% ...

After gaining 5.78% in January, the BioWorld Cancer Index reversed course, falling 4.74% year-to-date by the end of March. The index’s movement has closely tracked broader market trends. The Nasdaq ...

Since February 19th, there have been as many big biotech gainers as losers. A couple, like 2seventy Bio, which is developing a therapy for blood cancer, leapt from the bottom 100 to the top.

American pharma giant Bristol Myers Squibb (BMS) kicked off the month with its $286 million acquisition of U.S.-based 2seventy bio. BMS will begin a tender offer to acquire all outstanding shares of ...

Overview: 2seventy bio, Inc. is a cell and gene therapy company dedicated to researching, developing, and commercializing cancer treatments in the United States, with a market cap of $259.07 million.